Half-lifeNot well measured for TB-500. Full-length thymosin beta-4 given by IV lasted longer at higher doses in a human study.
Vial sizes5 mg, 10 mg
The simple version
What it does
It's meant to help injuries heal, based mostly on animal studies.
How people take it
People report 2–2.5 mg as a shot under the skin, twice a week for 4–6 weeks.
Know this
There are no human trials of it for injuries, and it's banned in tested sports.
What it is
Thymosin beta-4 is a protein your body makes in almost every cell, and it helps cells move to where a wound is. TB-500 is a lab-made version, usually a short active piece of it. What's sold as TB-500 can be either the short piece or the full protein, and the label doesn't always say which.
How it works
It helps cells crawl and change shape, so in animals repair cells can reach injured tissue. Animal studies also show it supports new blood vessels and calms swelling. None of this has been proven in people for injury repair.
What people use it for
Muscle, tendon and ligament injuries
General recovery from training
Wound healing
The evidence
Mostly animal studies
Most of the evidence comes from animals and cells. The full protein (not the short TB-500 piece) has had a little testing in people: an IV safety study in 40 healthy volunteers found it well tolerated, and eye-drop versions for dry eye had mixed results. There are no human trials of TB-500 shots for sports injuries, so the doses people use come from community practice, not studies.
We may earn a commission from these links. Counts include one syringe and two swabs per dose.
Stay safe
Side effects
Redness or irritation where you inject
Tiredness or a head rush after a dose (anecdotal reports)
Headache (anecdotal reports)
Unknown long-term effects
Skip it if
Past cancer or a current tumor (it helps cells move and grow new blood vessels, which tumors can use)
Pregnant or breastfeeding
Under 18
Athletes who get drug tested under WADA rules
Interactions
No studies have looked at how it mixes with other drugs in people
Get help right away for swelling of the face or throat, trouble breathing, chest pain, or a spreading, hot, red injection site.
Storage & legal
Storage
Powder: fridge or freezer, out of light. Once mixed with bacteriostatic water: fridge, use within about 4 weeks.
Legal status
FDA: Not approved. FDA removed thymosin beta-4 fragment from its Category 2 compounding risk list in April 2026. On July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding it to the 503A bulks list. That is advice only; FDA has not made it final.
Sport (WADA): Prohibited at all times (S2, growth factors). WADA names thymosin-β4 and its derivatives, such as TB-500.
Not exactly. TB-500 usually means a short lab-made piece of thymosin beta-4, though some products are the full protein. The human safety data is for the full protein, not the short piece.
Do I inject it near the injury?
It's thought to travel through the body, so most people inject it under the skin of the belly. There's no human evidence that the spot matters.
Will it show up on a drug test?
Yes. Sports drug-testing labs check for it, and it's banned at all times.
Sources
Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed 22074294
Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-9. PubMed 20536472
Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. 2015;9:877-84. PubMed 26056426
Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-6. PubMed 25826322
Sosne G, et al. Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries. Invest Ophthalmol Vis Sci. 2015;56(9):5110-7. PubMed 26241398